Tang Capital Management LLC Bluebird Bio, Inc. Transaction History

Tang Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.91 - $1.75 $728,000 - $1.4 Million	800,000 Added 47.06%	2,500,000 $3.2 Million
Q4 2023 Feb 14, 2024	SELL	$1.32 - $4.83 $7.5 Million - $27.4 Million	-5,682,827 Reduced 76.97%	1,700,000 $2.35 Million
Q2 2023 Aug 14, 2023	SELL	$2.79 - $5.03 $6.98 Million - $12.6 Million	-2,500,000 Reduced 25.3%	7,382,827 $24.3 Million
Q1 2023 May 15, 2023	BUY	$3.14 - $8.22 $16.5 Million - $43.1 Million	5,247,299 Added 113.2%	9,882,827 $31.4 Million
Q4 2022 Feb 14, 2023	SELL	$5.77 - $8.49 $7.36 Million - $10.8 Million	-1,275,159 Reduced 21.57%	4,635,528 $32.1 Million
Q2 2022 Aug 15, 2022	BUY	$2.94 - $5.23 $12.8 Million - $22.8 Million	4,360,687 Added 281.33%	5,910,687 $24.5 Million
Q1 2022 May 16, 2022	BUY	$4.07 - $10.6 $6.31 Million - $16.4 Million	1,550,000 New	1,550,000 $7.52 Million

162

79.9M

525K

634K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $40.1M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Tang Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tang Capital Management LLC with notifications on news.